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Combination of high-dose furosemide and 
hydrochlorothiazide in the treatment of refractory 
congestive heart failure
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Medicine, St Joseph Hospital, Veldhoven, The Netherlands
Objective We studied the synergism between high-dose 
furosemide and hydrochlorothiazide in patients with severe 
congestive heart failure and impaired renal function show­
ing diuretic resistance to a daily dose of furosemide of at 
least 250 mg.
Design and setting An open study. A general hospital in 
The Netherlands.
Methods In 20 patients with severe congestive heart 
failure (stage III—IV according to the New York Heart 
Association) with an oedematous mass of more than 5 kg 
and a proven diuretic resistance to high-dose furosemide, 
hydrochlorothiazide (25-100 mg daily) was added to the 
medication for 3-12 days, leaving the other medica­
tion unchanged. After correction of the hydration state, 
hydrochlorothiazide was withdrawn. Variables included 
body weight, serum electrolytes, renal function and 
natriuresis.
Results Addition of hydrochlorothiazide resulted in a 
mean (it standard deviation) body weight reduction of 
6*7 ±  3*3 kg per patient. Mean daily urine volume increased 
from 1899 dt 958 ml to 3065 ± 925 ml (P<0*001). Fractional 
sodium excretion increased significantly from 3-5 ±3-2% 
to 11*5 ±  9*0% (P<0-001), The most important side effect of 
this combination therapy appeared to be hypokalaemia. 
Mean endogenous creatinine clearance decreased (not 
significantly) from 32*7 ±  22*5 m l. min ~ 1 . 1*73 m “ 2 to 
27*6 ±  22-5 ml . min“ 1 , 1*73 m ~ 2.
Conclusions Addition of hydrochlorothiazide to high- 
dose furosemide is a powerful diuretic tool, even in patients 
with a significantly reduced renal function. Because of its 
potentially dangerous side effects (hypokalaemia), it should 
be used in a carefully controlled setting,
(Eur Heart J 1996; 17: 1867-1874)
Key Words: Diuretics, diuretic resistance, oedema, furo­
semide, heart failure, hydrochlorothiazide.
Introduction
In the majority of patients with congestive heart failure 
no causal treatment for the underlying disease is avail­
able, thus only symptomatic therapy remains, The basis 
of the management of decompensated patients consists 
of restriction of both physical activity and sodium intake 
together with pharmacological therapy. In the manage­
ment of patients with advanced chronic heart failure, 
pharmacological treatment comprises angiotensin con­
verting enzyme inhibitors» vasodilators, digitalis and 
diuretics111. Diuretics, most frequently the potent loop 
diuretics, are universally used once fluid retention 
occurs.
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The usually recommended doses o f loop diuretics 
will lead to clinical improvement in the majority of 
patients, but in some this fails to reduce oedema. In 
patients with refractory congestive heart failure, the 
glomerular filtration rate is often significantly reduced to 
a level of about 30 m l. min due to both p re-renal 
(low cardiac output, renal vasoconstriction due to sym­
pathetic excitation) and renal (arteriosclerosis) factorst2l  
In these cases, conventional doses of loop diuretic 
appear to be too low to create an adequate concen­
tration in the renal tubule, resulting in an insufficient 
diuretic response. In these patients, administration of 
high-dose furosemide (250 to 4000 mg per day) —  
supplied either orally or as a more effective continuous 
intravenous infusion — has been shown to be effective 
and safe[2,33.
However, in a few patients with severe congestive 
heart failure even chronic therapy with high-dose furo­
semide fails to reduce the volume of the extracellular 
compartment to the desired level and again diuretic
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Table 1 Characteristics o f  study patients and diuretic regimes
Patient
no.
Sex
M/F
Age
(years)
Cause
of
illness
Furosemide
dosage
(m g . d ay “ 1)
Other 
diuretics 
(mg. day- 1 )
Hydrochlorothiazide 
dosage 
(m g. d ay -1 )
Period of 
combination 
(days)
1 M 61 CM 2000 PO TRIAM: 50 100 8
2 M 71 CAD 2000 PO SPIRO: SO/AMILO: 10 100 4
3 M 58 CAD 2000 PO ---------- 50 3
4 M 64 CAD 4000 IV AMILO: 10 50/100 3/7
5 M 73 CAD + VD 2000 PO AMILO:5/TRIAM:50 100 4
6 M 66 CAD 500 PO 25/50/100 6/3/3
7 M 69 CAD 2000 PO SPIRO: 100 50 3
8 F 70 VD 500 PO AMILO:10 50 5
9 M 86 CAD 4000 IV TRIAM:50 100 3
10 M 78 CAD 1000 IV TRIAM:50 25 4
11 M 83 CAD 500 PO TRIAM: 50 25 4
12 M 86 CAD 500 PO AMILO;5 25 5
13 M 51 CM 500 PO SPIRO: 100 25 7
14 F 80 CAD 2000IV TRIAM:50 50 15
15 F 81 CAD 1000 PO 25 5
16 F 83 CAD 2000 IV ---------- 25 6
17 M 78 VD 2000 IV TRIAM:50 25 9
18 M 30 CM 3000 IV AMILO: 10 25 15
19 F 79 VD 250 PO AMILO: 5 25 5
20 F 69 CAD 500 PO ---------- 25 10
CM = cardiomyopathy; C A D -coronary  artery disease; VD=valvular disease; PO=supplied orally; IV-supplied intravenously; 
TRIAM = triamterene; AM ILO=amiloride; SPIRO= spironolactone.
resistance ensues. A combination of diuretics acting on 
different segments of the nephron may then be a possible 
approach to master diuretic resistance*
The synergism between loop diuretics and thi­
azides has been described in several studiest4~13]. How­
ever, in all studies concerning the synergism of diuretics, 
loop diuretic doses were relatively low (i.e. oral furo- 
semide lower than 500 mg . day -  *) and in most of these 
studies renal function was fair. While thiazides used as 
monotherapy are thought to be no longer effective when 
the glomerular filtration rate falls below approximately 
25 to 30 m l. min — 1[14,15], there are nevertheless limited 
data showing that addition of a thiazide to a loop 
diuretic increases natriuresis in patients with advanced 
renal failure110,161.
We studied the effects of the addition of hydro­
chlorothiazide to high-dose furosemide in patients with 
severe congestive heart failure who showed an impaired 
natriuretic response to high-dose furosemide (250- 
4000 mg), or who were already receiving the drug in 
combination with a diuretic acting on the collecting 
ducts.
Patients and methods
After approval of the protocol by the local ethics 
committee, we selected 20 inpatients (six female, 14 
male) with severe congestive heart failure (stage III 
(n=5) or IV (11=15) according to the New York Heart 
Association classification) who gave their informed 
consent for the study, which was performed between 
December 1989 and October 1994, All patients had an
estimated oedematous mass of at least 5 kg and diuretic 
resistance. Diuretic resistance was defined as a failure to 
lose weight and/or create a negative sodium balance 
despite bedrest, restricted salt and fluid intake, a diuretic 
regime of high-dose furosemide (250 to 4000 mg daily), 
administered orally or by continuous intravenous 
infusion, either or not in combination with potassium- 
sparing diuretics (triamterene, amiloride and/or 
spironolactone). All studied patients had been using 
high-dose furosemide for at least 2 weeks before the start 
of the study. Differences in diuretic regimes between the 
patients occurred because they were referred for treat­
ment by various departments. During the study 12 
patients used angiotensin converting enzyme inhibitors; 
in four patients enalapril was withdrawn soon after its 
introduction because of progressive renal impairment, 
while in two other patients enalapril caused sympto­
matic hypotension. In two others we could find no 
reason retrospectively for withdrawal of angiotensin 
converting enzyme inhibition. Ten patients used digoxin 
while none used dobutamine and/or low-dose dopamine.
The relevant patient characteristics are presented 
in Table 1. Mean age was 70-8 years (range 30 to 86 
years) and the mean body weight at the start of the study 
was 73*7 kg (55*2 to 96*8 kg). The underlying cause of 
heart failure was coronary artery disease (n= 13), valvu­
lar disease (n=3), cardiomyopathy (n = 3) and a combi­
nation of coronary artery disease and valvular disease 
(n= l). The left ventricular ejection fraction, estimated 
by cross sectional echocardiography, was less than 25% 
in all patients.
During the entire study the daily dietary sodium 
intake was limited to 80 mmol and the fluid intake to
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1500 ml. Physical examination including measurement 
of body weight, supine and standing blood pressures, 
pulse rate, central venous pressure (determined by visual 
inspection of the neck veins1171) and assessment of 
oedematous mass was performed daily. Patients were 
interviewed daily for recognition of side effects. The 
total daily output of urine was collected for creatinine, 
sodium, potassium chloride and protein measurements. 
Daily blood samples were taken to determine serum 
sodium, potassium chloride, bicarbonate, albumin, 
uric acid, creatinine and urea. Monitoring was started 
at least 2 days before administration and was con­
tinued until 2 days after withdrawal of hydrochloro­
thiazide. Hydrochlorathiazide, either 50 or 100 mg 
(creatinine clearance >25 m l. min ” 1 . 1 -73 m ~ 2: 
100 mg hydrochlorothiazide, creatinine clearance 
<25 m l. min “ 2 . 1 *73 m "2: 50 mg hydrochlorothi­
azide), was added, leaving dosages of other medication 
(other diuretics included) unchanged. Because three of 
the patients treated this way showed signs of dehydra­
tion several days after withdrawal of hydrochlorothi­
azide, we decided to lower the starting dose to 25 mg 
hydrochlorothiazide in an attempt to avoid accumula­
tion of hydrochlorothiazide. In two patients the dosage 
of hydrochlorothiazide was increased during the 
study, because the initial dose appeared to be ineffec­
tive. Potassium supplements were given when serum 
potassium was lower than 3-5 mmol. 1~ \
Patients were treated with a combination of 
high-dose furosemide and hydrochlorothiazide during a 
period varying from 3 to 12 days. When the hydration 
status of a patient was judged appropriate, hydro­
chlorothiazide was stopped. In two patients the 
hydrochlorothiazide medication was discontinued de­
spite insufficient weight loss. Because there was a signifi­
cant increase in natriuresis, we concluded that in these 
two patients weight loss was not achieved due to poor 
compliance with the dietary restrictions.
Results are expressed as mean ± SD. The 
Wilcoxon test was performed when the parameters 
before and after combined treatment with high-dose 
furosemide and hydrochlorothiazide were compared.
Results
In the period preceding the combination therapy, 
when only high-dose furosemide was administered, 
natriuresis was low in most patients indicating that 
sodium-retaining mechanisms were activated. However, 
four patients showed a natriuresis of more than 
125 mmol. day“ 1 without weight reduction (range 137- 
188 mmol. 24 h~ *), which can be explained by poor 
compliance with the dietary restriction. The low natriu­
resis in the other patients (53 ±  32 mmol. 24 h ~ i, rang­
ing from 7 to 100 m m ol. 24 h “ {) confirms the diuretic 
resistance to high-dose furosemide. A typical example of 
the effect of the combination therapy is shown in Fig. 1. 
The average weight reduction during the 5 days preced­
ing the addition of hydrochlorothiazide was 0-6 ±  1 *2 kg
(n = 17); in three patients hydrochlorothiazide had been 
added already, 2 days after admission to hospital, be­
cause of the severity of the symptoms. Patients were 
treated with a combination of high-dose furosemide and 
hydrochlorothiazide during a period varying from 3 to 
12 days. During this treatment period, body weight 
reduction varied from 2*2 to 14*0 kg (6*7 ± 3*3 kg). 
After withdrawal of hydrochlorothiazide, the longest 
period of weight stabilization was in excess of 2 weeks 
in 16 patients. During the use of combined diuretic 
therapy, mean fractional sodium excretion increased 
from 3*5 ± 3*2% to 11*5 ±90% (P<0-001) (Table 2). 
After stopping the administration of hydrochloro­
thiazide, fractional sodium excretion returned to the 
previous low level. However in three patients, using 
either 100 mg or 50 mg hydrochlorothiazide, the in­
creased natriuresis lingered on, resulting in dehydration 
more than 2 days after stopping the combination 
therapy.
All patients in this study had a reduced 
renal function. Improvement of the hydration state 
of these patients induced a (not significant) re­
duction in endogenous creatinine clearance 
(32*7 ± 22*5 m l. min“'1 . 1*73 m “ 2, (range 4-4 to 
110*7 m l. min ~ 1. 1-73 m " 2) prior to combination 
therapy vs 27*6 ± 22-5 m l. min " 1. 173 m _2 (range 8*9 
to 100*8 m l. m in~1. 1*73 m “ 2 after)). In six patients 
correction of the hydration state resulted in an improve­
ment of endogenous creatinine clearance.
Hypokalaemia was an important side effect of 
the simultaneous administration of high dose furo­
semide and hydrochlorothiazide; the elevated potassium 
excretion (65 ±33 mmol. day ~ 1 prior vs 115 ±  55 
during combined administration) resulted in hypo­
kalaemia in 15 patients (serum potassium lower than 
3*5 mmol. 1“ 1), which could only be corrected by 
enlarging the potassium intake. The lowest mean 
serum potassium measured during the combination 
therapy was 3-3 ± 0*5 mmol .1“ 1 (ranging from 2*2 to 
4*2 mmol. I" 1). It should be noted, that before hydro­
chlorothiazide was added to the medication, most of the 
patients were already using potassium-sparing diuretics 
(see Table 1) which failed to prevent the development of 
serious hypokalaemia.
On average, the patients were mildly hyponatrae- 
mic (mean serum sodium 136 ± 5 mmol. 1” 1 (reference 
value 138 to 144 mmol. P  *)), which was (not signifi­
cantly) aggravated during the combination therapy 
(134 ±  8 mmol. 1 ~ *). Although serum uric acid concen­
tration increased (not significantly) during the combined 
use of high-dose furosemide and hydrochlorothiazide 
(0*67 ± 0*26 mmol. 1 ~ 1 prior vs 0*79 ± 0.27 m m ol. P 1 
post, P<0’05), none of the patients developed attacks of 
gouty arthritis.
No side-effects of this therapy, in particular 
hearing loss or tinnitus were recorded. No hypotensive 
episodes were observed during therapy.
Eight patients were reallocated from NYHA 
class IV to III as a result of the treatment, and one of 
five class III patients improved to class II. Fourteen
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Figure 1 Treatment results in a 71-year-old man with chronic heart failure 
(CHF) caused by coronary artery disease (CAD, patient 2). The lowest panel 
shows the diuretic therapy: to 2 g furosemide (F) per day administered orally as 
the basic regimen, 100 mg hydrochlorothiazide (HCT) was added on 4 consecu­
tive days. The fixed dose of spironolactone (50 mg) and amiloride (10 mg) is not 
shown. The upper panel shows the daily urine volume (UV), natriuresis (US) 
and the course of serum sodium (SS) and serum potassium (SP), respectively. 
The dotted horizontal line represents the daily dietary sodium intake. Note that 
the lowest serum potassium value was 2*2 mmol. 1 “ which increased after the 
potassium chloride intake was raised to 160 mmol per day, in addition to the 
potassium sparing diuretics. The upper middle panel shows the effects of 
treatment on body weight (BW) and central venous pressure (CVP). The lower 
middle panel shows the daily creatinine excretion (UCr), the course of serum 
creatinine (SCr) and urea (SU) levels, and endogenous creatinine clearance
(ECC).
Eur Heart J, Vol. 17, December 1996
Diuretic synergism 1871
Table 2 Effects o f  combined administration o f high-dose furosemide and hydro­
chlorothiazide
Before During After
treatment treatment treatment
BW (kg) 73-7 ±
BW reduction (k g . day ') 0*1 ±
UV (m l. 24 h ~ ') 1899 ±
Usodium (mmol .24 h -1 ) 85 ±
UPolilssium (m m ol. 24 h ') 65 ±
Uchioridc (m m ol. 24 h ') 100 ±
FeNa (%) 3*5 db
SSodh.m (m m ol. 1" ’) 136 ±
A Æ
^Potassium (mmol . 1 ~ 0
SChloride (mmol . 1” ')
4-1 ±
94 ±
^Bicarbonate (mmol .1 )
^Creatinine • 1 )
28 ±
148 ±
Surea («llDOl . 1~ ') 17 ±
ECC (m l. min ~ 1 1.73 m “ 2) 32*7 ±
^Albumin (ß *  ^ ) 33-0 ±
Suric Acid (mmol r ') 0*67 dr
13*9 67*0 ±13*3
0.3** 1*3 ±  0*8}
958 3065 ±  925} 2000 ±  666
58 206 ±  84Î 84 ± 5 8
33 115 ±  55} 83 ± 3 3 *
67 243 dfc 94} 116 ± 6 5
3*2 11*5 ± 9 -0 } 2*9 ±1*9
5 134 ± 8
0-5 3*3 ±0*5} 4*2 ±  0*7
5 86 ± 8}
2 33 ± 4 *
69 177 ±  78*
6 26 ± 10}
22*5 27*6 ±  22*5
5-2 35*6 ±3*9*
0-26 0*79 ±  0*27}
BW=body weight; UV=urine volume; USodilim, etc=urine electrolyte excretion; FeNa=fractional 
sodium excretion; ECC=endogenous creatinine clearance; SSodium, etc=serum concentrations. 
Results are mean ±  standard deviation.
*~_p<0'05, t = -^<0,01, | = / ><0-001, compared to before treatment with the Wilcoxon-test. 
**=n=17.
The value of serum potassium during treatment represents the nadir of serum potassium during 
treatment. Administration of potassium supplements was started at a serum potassium value of 
3*5 mmol. I - 1 .
patients were fit enough to be discharged from hospital. 
Fifteen patients died with a mean survival of 122 ± 129 
days (ranging from 0 to 404 days) after termination of 
the high-dose furosemide and hydrochlorothiazide treat­
ment. Five patients were still alive after a 1-year 
follow-up period.
Discussion
In the past 20 years the synergism between loop diuretics 
and thiazides has been described in several studies^13]. 
However, administration of loop diuretics in these 
studies in relatively low doses (i.e. oral furosemide lower 
than 500 mg . day “ ]) and to our knowledge this is the 
first study describing this synergism in patients with 
severe congestive heart failure and advanced renal fail­
ure showing diuretic resistance to high-dose furosemide.
Under physiological conditions, approximately 
25% of the filtered NaCl is reabsorbed in the loop of 
Henle, while 5% to 10% is reabsorbed in the distal 
tubule. However, the distal tubules have the ability to 
increase NaCl transport capacity when the delivered 
load in this segment of the nephron increases118"20l  
Furosemide acts from the tubular lumen on the thick 
ascending limb of the loop of Henle and blocks the 
major part of the sodium reabsorbing capacity in this 
part of the nephron. As a result, more sodium is 
delivered to the distal parts of the nephron. In rats, a 
chronic increment of sodium delivery to the distal 
tubules appeared to induce hyperplasia of the cells and
an increase of the sodium transport capacity in this 
segment118’21,22], It was shown that the sodium retaining 
capacity of the distal convoluted tubule was increased 
substantially after chronic use of loop diuretics and 
this seems to be an important cause of diuretic 
resistance^18,19,21,221.
Administration of high-dose furosemide, prefer­
ably given as a continuous intravenous pump infusion, 
has been demonstrated to be a safe, efficient and con- 
trollable method of overcoming diuretic resistance to 
usually recommended doses (40 to 250 mg daily) in 
chronic heart failurei2,3l  The patients presented here all 
used high doses of furosemide (at least 250 mg daily), 
administered either orally or by continuous intravenous 
pump infusion, for at least 2 weeks, prior to combined 
use of high-dose furosemide and hydrochlorothiazide. 
During this phase, fractional sodium excretion was low 
in all patients, reflecting diuretic resistance. It is also 
possible that diuretic resistance to high-dose furosemide 
was the result of decreased tubular excretion of furo­
semide, because we did not measure renal furosemide 
excretion. In an animal experimental study it was shown 
that triamterene (and not amiloride or spironolactone) 
inhibits the tubular secretion of furosemide in a non­
competitive manner1231. However, in the latter study, as 
well as in the studies on the coadministration of furo­
semide and triamterene in humans, this coadministra­
tion resulted in increased natriuresist24>25l  Therefore, it is 
unlikely that administration of triamterene together with 
high-dose furosemide (n=7) will attribute the diuretic 
resistance to high-dose furosemide, as observed in the
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patients in this study. Another possible cause for this 
diuretic resistance to high-dose furosemide could be a 
reduced response in the loop of Henle. However, the 
striking natriuretic response during combined use of 
high dosages of furosemide and hydrochlorothiazide in 
the patients presented here suggests that these furo­
semide doses are able to reduce sodium reabsorption in 
the loop, even after prolonged use.
In most of the studies describing the synergism 
between loop diuretics and thiazides, the former was 
combined with metolazone, a diuretic agent which is 
registered in only a few countries in Europe. Metolazone 
is structurally related to the benzothiadiazines, with 
pharmacological effects similar to hydrochlorothiazide 
[14,26] yjie major action of hydrochlorothiazide, like
other thiazides, is from the luminar surface on the distal 
convoluted tubule. Used as monotherapy, hydrochloro­
thiazide has no significant diuretic effect on diuresis 
in patients with a considerably impaired renal func­
tion (endogenous creatinine clearance lower than 
30 m l. min-  1 . 1*73 m ” 2)tl5,26l  One patient was subse­
quently treated with high-dose furosemide alone, 
hydrochlorothiazide alone and a combination of high- 
dose furosemide and hydrochlorothiazide (data not 
shown). Only the latter treatment resulted in increased 
natriuresis.
For these reasons, it seems unlikely that hydro­
chlorothiazide could by itself account for the natriuresis 
during the period of combined use of furosemide and 
hydrochlorothiazide in the patients presented. There­
fore, it is most probably the increased sodium reabsorb­
ing capacity of the distal tubules and the collecting ducts 
in these patients that causes a diminished natriuretic 
response to high-dose furosemide. Evidence for the 
presence of this mechanism in humans was found in a 
previous study[273. Animal studies showed that even the 
increased sodium reabsorbing capacity of the distal 
tubule after chronic furosemide treatment could be 
almost completely blocked by thiazides119,281.
Thus, the simultaneous administration of high- 
dose furosemide and hydrochlorothiazide leads to 
decreased sodium reabsorption in the loop of Henle and 
to a block of the increased sodium transport capacity in 
the distal tubule, resulting in a significant increase in 
fractional sodium excretion.
The addition of hydrochlorothiazide in patients 
after chronic administration of loop diuretics (all 
patients in this study used high-dose furosemide for at 
least 2 weeks) instead of simultaneous introduction of 
the two diuretic drugs might be even more powerful 
because of the increased sodium reabsorbing capacity 
of the distal tubule in these patients. This increased 
reabsorbing capacity could also explain why hydrochlo­
rothiazide is still effective in those patients with a 
reduction of the renal function below the level where 
thiazides as monotherapy are reported to become in­
effective. This observation is confirmed by the results of 
a recent study, showing that coadministration of thi­
azides increased efficacy of loop diuretics in patients 
with advanced renal failure^163.
In this study, we did not analyse the effects of the 
addition of a diuretic acting specifically on the proximal 
tubule, to furosemide and hydrochlorothiazide on 
natriuresis. In some of our patients we observed that 
the natriuretic effect of the combination of diuretics 
described persisted some days after administration 
of hydrochlorothiazide was stopped. Three patients 
showed signs of dehydration some days after withdrawal 
of hydrochlorothiazide, and required intravenous rehy­
dration. The reason for this prolonged effect might be 
the reduced renal clearance of hydrochlorothiazide in 
these patients (who all used 50 mg or 100 mg hydrochlo­
rothiazide) with an impaired renal function resulting in a 
longer half life and accumulation of hydrochlorothi­
azide1261. A better cardiac output after amelioration of 
the hydration state or a stronger osmotic diuretic effect 
of the higher serum urea are other possible explana­
tions for the improved natriuresis after the combined 
treatment.
It should be emphasized that the combination of 
high-dose furosemide and hydrochlorothiazide should 
only be used under carefully controlled circumstances. 
Besides side-effects like hyponatraemia, alkalosis, dehy­
dration and loss of renal function, severe hypokalaemia 
should be avoided most of all. Daily clinical and labo­
ratory examinations should be performed until a new 
equilibrium has been achieved. The (not significant) 
reduction in renal function can be caused by slight 
dehydration or by a direct effect of hydrochlorothi­
azide^93. Since the appearance of ototoxic side effects is 
positively related to the plasma furosemide concen­
tration, patients treated with intravenously administered 
high-dose furosemide and a reduced renal function (and 
thus a reduced renal clearance of furosemide) are at risk 
for ototoxicity[30]. On the other hand, in an earlier study 
on the use of high-dose furosemide in chronic haemo- 
dialysis patients there were no audiometric signs of 
ototoxicity[3l]. To avoid ototoxic plasma concentrations, 
the patients in this study were mainly treated orally and 
in all of those receiving furosemide intravenously, furo­
semide was administered as a continuous infusion. None 
of the patients in this study complained of hearing loss 
or tinnitus. However, this study did not comprise an 
audiometric evaluation.
Left ventricular performance was significantly 
reduced in all patients studied. They all had end-stage 
congestive heart failure with a very short life expectancy. 
Whether survival was prolonged by combined use of 
high-dose furosemide and hydrochlorothiazide, which is 
merely a symptomatic therapy, could not be proven 
because of the absence of a matched control group. The 
quality of life was definitely improved by reducing 
peripheral oedema and avoiding symptoms of lung 
oedema, as demonstrated by the reduction in NYHA 
class. On the other hand, this therapy may worsen the 
prognosis. Although chronic diuretic therapy may lead 
to a decrease in the hyperactivity of the sympathetic 
nervous system/323, diuretic treatment will cause further 
stimulation of the renin angiotensinogen system, causing 
negative haemodynamic effects[33-35]. To reduce these
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effects, angiotensin converting enzyme inhibitors and 
diuretics should be used simultaneously, whenever poss­
ible. Furthermore, diuretic therapy can be associated 
with cardiac arrest 3^61.
A further benefit of this combination therapy is 
that an overhydrated state could be treated without 
the use of invasive techniques such as haemofiltration, 
haemodialysis or continuous ambulatory peritoneal 
dialysis, for example to bridge a period to a heart 
transplantation, as in one of the patients included in this 
study.
In conclusion, we observed that high-dose furo­
semide (500 to 4000 mg daily dosage) and hydrochloro­
thiazide have a powerful synergistic diuretic effect in 
patients with severe congestive heart failure showing 
diuretic resistance to high-dose furosemide despite a 
significantly reduced renal function (mean endogenous 
creatinine clearance 32*7 ±  22-5 m l. min~ 1. 1*73 m ~ 2). 
Because of its side effects, this combination therapy 
should only be used in a carefully controlled setting and 
should be reserved for a selected group of patients not 
responsive to other diuretic regimes.
We thank Professor P. Smits from the Department of Pharma­
cology, University of Nijmegen, for his constructive comments and 
criticism.
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